Cardiff Oncology to Present at the Jefferies London Healthcare Conference
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company, will present at the Jefferies London Healthcare Conference from November 15-17, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company, will present at the Jefferies London Healthcare Conference from November 15-17, 2022. The presentation is scheduled for November 15 at 3:55 PM GMT (10:55 AM ET) and will include a corporate presentation followed by a Q&A session. The company focuses on PLK1 inhibition in developing therapies for cancers such as KRAS/NRAS-mutated metastatic colorectal cancer and metastatic pancreatic ductal adenocarcinoma. A replay will be available on their website for 90 days.
Details
News Market Reaction – CRDF
The recorded move for CRDF in the trading session of this news was +0.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Jefferies London Healthcare Conference, which is taking place in London, UK from November 15 – 17, 2022.
Details of the presentation can be found below.
Jefferies London Healthcare Conference
Date: | Tuesday, November 15, 2022 |
Time: | 3:55 PM GMT / 10:55 AM ET |
Format: | Corporate Presentation and Q&A Session |
Webcast Link |
A replay of the presentation will be available by visiting the "Events" section of the Cardiff Oncology website and will be archived for 90 days.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor we are evaluating in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as KRAS/NRAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC). These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.
Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-present-at-the-jefferies-london-healthcare-conference-301671205.html
SOURCE Cardiff Oncology, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.